Table 3 Factors associated with CD105/CD31 expression ratio – univariable analysis
From: Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma
Variables | Number of patients (%) | Univariable Analysis | ||
|---|---|---|---|---|
Coefficient | IC | P value | ||
  ≥ 1 < 10 (ref) | 21 (70) | – | – | – |
  < 1 ≥ 10 | 9 (30) | − 0.10 | − 0.77;0.56 | 0.757 |
Histology | ||||
 ARMS (ref) | 12 (40) | – | – | – |
 ERMS | 18 (60) | − 0.49 | − 0.89;-0.08 | 0.019 |
Tumor size | ||||
  ≤ 5 cm (ref) | 10 (33) | – | – | – |
  > 5 cm | 20 (77) | − 0.28 | − 0.83;0.27 | 0.313 |
Primary site (location) | ||||
 Favorable (ref) | 12 (40) | – | – | – |
 Unfavorable | 18 (60) | 0.01 | − 0.45;0.47 | 0.962 |
COG Risk Group | ||||
 Low (ref) | 8 (27) | – | – | – |
 Intermediate | 16 (53) | 0.13 | − 0.53;0.79 | 0.682 |
 High | 6 (20) | − 0.01 | − 0.84;0.81 | 0.977 |
VEGF score | ||||
 1–2 (ref) | 19 (63) | – | – | – |
 3–4 | 11 (37) | 0.41 | − 0.04;0.85 | 0.072 |
Status | ||||
 Alive (ref) | 22 (73) | – | – | – |
 Dead | 8 (27) | 0.53 | 0.10; 0.95 | 0.016 |